Celltech and Chiroscience in pounds 700m biotech merger
Wednesday 16 June 1999
Celltech Chiroscience will be the UK's largest biotechnology company and the largest pharmaceuticals company after AstraZeneca, which is valued at pounds 45bn.
The all-paper deal follows the merger last month of cash-strapped biotech tiddlers Proteus and Therapeutic Antibodies. However, it is unusual in that unlike their peers, Celltech and Chiroscience have strong balance sheets and no apparent need to merge.
Dr John Padfield, Chiroscience's chief executive said the merger was driven by both companies' need for critical mass. "There's an arms race in drugs discovery and size matters," he said.
Peter Fellner, Celltech's chief executive who is to retain his role in the new group, said: "We will now be competing with some parts of what a major pharmaceutical company does, and our drug development pipeline will be equivalent too."
Celltech's strengths are in molecular biology and Chiroscience's is in its gene-based technologies.
Dr Padfield is leave the group on completion of the deal to join the board of Nycomed Amersham.
The discussions which led to yesterday's announcement began after John Jackson, Celltech's chairman who is to retain his role in Celltech Chiroscience, unexpectedly bumped into Chiroscience chairman Hugh Collum, who becomes deputy chairman, at breakfast in a London hotel last autumn.
Based on Celltech's closing price of 472.5p and market capitalisation of pounds 365m, the deal values Chiroscience at pounds 331m, or 293p per share, an 18.3 per cent premium to Monday's closing price of 259p. Chiroscience shareholders will receive 62 Celltech shares for every hundred Chiroscience shares.
The principal benefit of the merger will be the capability of the enlarged scientific base of 400 research staff to handle larger drug discovery projects. In addition, the broadened portfolio of drugs in development minimises the groups' dependence on the success of any one drug. The group said there would be few redundancies.
Analysts said Chiroscience stood to gain more from the deal because it had few premium products in its development pipeline to follow up Chirocaine, its anaesthetic formulation expected to reach the market by year-end.
Yesterday the group announced marketing agreements with Purdue Pharma and Abbott Laboratories, both US-based pharmaceuticals groups, to distribute Chirocaine in the US and Europe respectively. Celltech Chiroscience said its challenge now was to attract young, creative scientists who were traditionally flocked to smaller, entrepreneurial companies.
However, Mr Jackson hinted the days of the small biotech company were coming to a close and the group would be considering making acquisitions. "In a lot of boardrooms people will be thinking about doing deals now," he said. "People have been saying something was going to happen for several years. Until now, there's been almost a paralysis."
Outlook, page 19
- 1 Autistic teenager beaten up by bullies makes them watch 20-minute video about autism
- 2 Nick Kyrgios calls former Olympian Dawn Fraser a 'blatant racist' after she tells Wimbledon star to 'go back where their parents came from'
- 3 World learns of app that shows you who unfriended you on Facebook, app promptly crashes
- 4 Chris Moyles reportedly set to make radio comeback with new breakfast show on XFM
- 5 The Greece debt crisis explained in less than 100 words
Florida man sentenced to two-and-a-half years for having sex on the beach in front of a child
Autistic teenager beaten up by bullies makes them watch 20-minute video about autism
Tube strike July 2015: Is it still on? Everything you need to know about the industrial action
Eiji Tsuburaya: Godzilla co-creator honoured in today's interactive Google Doodle
Florida teacher sentenced to 22 years in prison for sexually abusing three pupils
More Britons believe that multiculturalism makes the country worse - not better, says poll
Osborne to cap family benefits at £23,000 – announced ahead of his post-election Budget
Nathan Collier: Montana man inspired by same-sex marriage ruling requests right to wed two wives
Forget little green men – aliens will look like humans, says Cambridge University evolution expert
Girl, 7, stares down hate preacher at Ohio festival with pro-LGBT rainbow flag gesture
Sickness and disability benefits could be reduced by £30 a week as part of £12bn welfare cuts
iJobs Money & Business
£40000 - £95000 per annum: Recruitment Genius: This is an exciting opportunity...
competitive: SThree: Are you passionate about sales?Do you have a keen interes...
£17000 - £30000 per annum: Recruitment Genius: This is an exciting opportunity...
£15000 - £17000 per annum: Recruitment Genius: This company offers a range of ...